EcoDrugPlus

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSCVAG00000005921
Gene Symbol: LOC107091052
3 Cross references
205 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCVAG00000010094
Gene Symbol: TOP1
3 Cross references
201 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCVAG00000009497
Gene Symbol: EML4
4 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCVAG00000010276
Gene Symbol: EPHA3
3 Cross references
211 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCVAG00000004899
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSCVAG00000015604
Gene Symbol: FAU
3 Cross references
299 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCVAG00000023212
Gene Symbol: FYN
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSCVAG00000002529
Gene Symbol: GPR119
2 Cross references
176 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSCVAG00000001325
Gene Symbol: GPR84
3 Cross references
114 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCVAG00000006573
Gene Symbol: HCK
3 Cross references
160 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSCVAG00000002739
Gene Symbol: JAK1
3 Cross references
214 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSCVAG00000000414
Gene Symbol: JAK2
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).